Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression?
- 31 August 2003
- journal article
- review article
- Published by Elsevier in International Journal of Cardiology
- Vol. 90 (2-3) , 133-140
- https://doi.org/10.1016/s0167-5273(02)00565-x
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Peroxisome-proliferator-activated receptor-α (PPARα) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulinBiochemical Journal, 2002
- PPARγ ligands, troglitazone and pioglitazone, up‐regulate expression of HMG‐CoA synthase and HMG‐CoA reductase gene in THP‐1 macrophagesFEBS Letters, 2002
- PPARγ Is Not a Critical Mediator of Primary Monocyte Differentiation or Foam Cell FormationBiochemical and Biophysical Research Communications, 2002
- Peroxisome proliferator-activated receptor gamma (PPARγ) activation and its consequences in humansToxicology Letters, 2001
- Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive TissuesEndocrinology, 2001
- Peroxisome proliferator–activated receptor γ ligands and atherosclerosis: ending the heartacheJournal of Clinical Investigation, 2000
- Peroxisome Proliferator–Activated Receptor-γ Ligands Inhibit Nitric Oxide Synthesis in Vascular Smooth Muscle CellsHypertension, 2000
- Transcription-Modulating DrugsHypertension, 1998
- Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.Journal of Clinical Investigation, 1995
- Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeysDiabetes, 1994